H.C. Wainwright lowered the firm’s price target on RVL Pharmaceuticals to $3 from $4 and keeps a Buy rating on the shares post the Q2 report. The analyst lowered fiscal 2023 and 2024 estimates for net Upneeq revenues to $30.6M and $37.9M, from $48.4M and $76.3M, respectively. The firm now models Upneeq peak sales at $445.1M in 2035.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVLP:
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- RVL Pharmaceuticals prices $5M registered direct offering
- RVL Pharmaceuticals reports Q2 EPS (24c), consensus (11c)
- RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review
